Latest Close
$10.56
News
AGMB
AgomAb Therapeutics NV News
This news view pulls recent coverage and headlines tied to AGMB.
1y Change
-$4.09 (-27.92%)
Market Cap
$520,058,656.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
none
Agomab to Participate in Upcoming Conferences
GlobeNewswire • May 14, 2026
Read articleAgomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
GlobeNewswire • Apr 23, 2026
Read articleAgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447
Insider Monkey • Apr 12, 2026
Read articleAgomAb Says Investigational Fibrosis Drug AGMB-447 Receives US Patent
MT Newswires • Mar 26, 2026
Read articleAgomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
GlobeNewswire • Mar 26, 2026
Read articleEuropean Equities Traded in the US as American Depositary Receipts Higher Wednesday
MT Newswires • Feb 18, 2026
Read article